ARTICLE
7 January 2020

Overcoming Sections 101,102, 103 Conundrum For Biotech And Chemical Patents: Practical Guide In 2020

PC
Pearl Cohen Zedek Latzer Baratz

Contributor

Pearl Cohen Zedek Latzer Baratz logo
Pearl Cohen is an international law firm with offices in Israel, the United States, and the United Kingdom. Our strength is derived from decades of legal experience and an intimate knowledge of the cutting edge technological, legal, and transactional issues facing our clients in local and cross border matters. This combination of experience and knowledge allows us to provide sound and innovative advice to clients worldwide.
She will also discuss the important issues surrounding this significant topic including its impact on Biotech and Chemical Patents.
United States Intellectual Property
To print this article, all you need is to be registered or login on Mondaq.com.

On January 14th, 2020, Leslie Kushner, Counsel in the Litigation Group at Pearl Cohen's New York office, will present a webcast titled "Overcoming Sections 101,102, 103 Conundrum for Biotech and Chemical Patents: Practical Guide in 2020" presented by The Knowledge Group.

Leslie and her co-presenter will provide an in-depth analysis of the fundamentals as well as recent developments in Overcoming Sections 101,102, 103 Conundrum for Biotech and Chemical Patents. She will also discuss the important issues surrounding this significant topic including its impact on Biotech and Chemical Patents.

Key issues that will be addressed include:

  • Guiding Principles for Patent Eligibility
  • Updated Framework for Patent Eligibility
  • Section 101, 102, & 103 Conundrums
  • Impacts on Biotech and Chemical Patent
  • What Lies Ahead

For more information, or to register for this event, please click here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More